Alexandra C. Battersby

Alexandra C. Battersby

Auto-generated profile, based on publicly available information

Alexandra C. Battersby

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2013 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ABA. C. Battersby
A. C. Battersby
CCC. M. Cale
C. M. Cale
DGDavid Goldblatt
David Goldblatt
AGA. R. Gennery
A. R. Gennery

2 March 2017 in BMJ
Verified
Journal Article
Closed access
PDF file
IHIram J. Haq
Iram J. Haq
ABAlexandra C Battersby
Alexandra C Battersby
KEKatherine Eastham
Katherine Eastham
MMMichael McKean
Michael McKean

1 August 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ABAlexandra C. Battersby
Alexandra C. Battersby
HBHelen Braggins
Helen Braggins
MPMark S. Pearce
Mark S. Pearce
CCCatherine M. Cale
Catherine M. Cale
SBSiobhan O. Burns
Siobhan O. Burns
AGAndrew R. Gennery
Andrew R. Gennery

25 April 2019 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
FVFabian J. S. van der Velden
Fabian J. S. van der Velden
ABAlexandra Battersby
Alexandra Battersby
LPLucia Pareja-Cebrian
Lucia Pareja-Cebrian
NRNicholas Ross
Nicholas Ross
SBStephen L. Ball
Stephen L. Ball
MEMarieke Emonts
Marieke Emonts
Paediatric focal intracranial suppurative infections are uncommon but cause significant mortality and morbidity. There are no uniform guidelines regarding antibiotic treatment. This study reviewed management in a tertiary healthcare centre in the United Kingdom and considers suggestions for empirical treatment. A retrospective, single-centre cohort review of 95 children (< 18 years of age) with focal intracranial suppurative infection admitted between January 2001 and June 2016 in Newcastle upon Tyne, United Kingdom. Microbiological profiles and empirical antibiotic regimens were analysed for coverage, administration and duration of use. Mortality and neurological morbidity were reviewed. Data was analysed using t-tests, Mann-Whitney U tests, independent-samples median tests, and χ2-tests where appropriate. P-values < 0.05 were considered statistically significant. Estimated annual incidence was 8.79 per million. Age was bimodally distributed. Predisposing factors were identified in 90.5%, most commonly sinusitis (42.1%) and meningitis (23.2%). Sinusitis was associated with older children (p < 0.001) and meningitis with younger children (p < 0.001). The classic triad was present in 14.0%. 43.8% of 114 isolates were Streptococcus spp., most commonly Streptococcus milleri group organisms. Twelve patients cultured anaerobes. Thirty one empirical antibiotic regimens were used, most often a third-generation cephalosporin plus metronidazole and amoxicillin (32.2%). 90.5% would have sufficient cover with a third generation cephalosporin plus metronidazole. 66.3% converted to oral antibiotics. Median total antibiotic treatment duration was 90 days (interquartile range, 60–115.50 days). Mortality was 3.2, 38.5% had short-term and 24.2% long-term neurological sequelae. Paediatric focal intracranial suppurative infection has a higher regional incidence than predicted from national estimates and still causes significant mortality and morbidity. We recommend a third-generation cephalosporin plus metronidazole as first-choice empirical treatment. In infants with negative anaerobic cultures metronidazole may be discontinued.

18 April 2016 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
BBBranwen A. Bryan
Branwen A. Bryan
ABAlex Battersby
Alex Battersby
BSBenjamin Martin James Shillitoe
Benjamin Martin James Shillitoe
DBDawn Barge
Dawn Barge
HBHelen Bourne
Helen Bourne
AGAndrew Gennery
Andrew Gennery
Patients with congenital agammaglobulinemia, characterized by a defect in B lymphocyte differentiation causing B alymphocytosis, require life-long IgG replacement. There is scant literature regarding the effectiveness of IgG treatment at preventing mucosal (particularly sinopulmonary tract) infection and whether current management adequately restores “normal” health and quality of life (QoL). We aimed to document infective episodes pre- and post-commencing IgG replacement, determine any change in lung function and structure and assess respiratory status and QoL in a cohort of patients treated in Newcastle.

23 March 2017 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ABAlexandra C. Battersby
Alexandra C. Battersby
AMAlexander J. Martin
Alexander J. Martin
JTJessica Tarn
Jessica Tarn
FNFai W. Ng
Fai W. Ng
CCCatherine M. Cale
Catherine M. Cale
AGAndrew Gennery
Andrew Gennery